title: Postoperative radiation therapy after radical prostatectomy for prostate carcinoma.
abstract: BACKGROUND
  The role and benefit of adjuvant radiation therapy after radical prostatectomy is unclear. This role was evaluated in 58 patients who, after undergoing radical prostatectomy for prostate carcinoma, had local extension of disease beyond the prostate or positive surgical margins. Thirty-nine patients treated surgically alone were compared with 19 patients who received adjuvant postoperative radiation therapy. All patients were followed for at least 5 years, and 50 patients had 10-year follow-ups.
  
  
  RESULTS
  At 10 years, the actuarial local failure rate was 31% for patients treated with prostatectomy alone versus 6% for the group receiving postoperative radiation therapy (P less than 0.05). The actuarial survival and metastasis-free survival were similar for both groups. When patients with involved lymph nodes were excluded from analysis, the addition of radiation therapy resulted in improved recurrence-free survival (91% versus 46% at 10 years, P = 0.04) and in a trend toward improved metastasis-free survival (91% versus 55%, P = 0.08). Complications occurred in similar frequencies in both groups.
  
  
  CONCLUSIONS
  In patients with local disease extension or positive surgical margins after radical prostatectomy, adjuvant radiation therapy improved local control and was administered with acceptable side effects.
authors.affiliation: Department of Radiation Oncology, Palo Alto Medical Clinic, CA 94301.
authors.forename: R
authors.initials: R
authors.lastname: Meier
authors.forename: R
authors.initials: R
authors.lastname: Mark
authors.forename: L
authors.initials: L
authors.lastname: St Royal
authors.forename: L
authors.initials: L
authors.lastname: Tran
authors.forename: G
authors.initials: G
authors.lastname: Colburn
authors.forename: R
authors.initials: R
authors.lastname: Parker
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D016019:Survival Analysis